网站首页
概要
ClonaCell™-HY Medium A is a serum-containing liquid medium formulated for the growth and expansion of parental myeloma cells prior to fusion and for the growth of stable hybridoma clones post-selection. This medium has been verified for use during mouse and rat hybridoma development and reportedly is compatible for production of hybridomas using lymphocytes from a variety of host animals including human, mouse, rat, and hamster.
技术资料
| Document Type | 产品名称 | Catalog # | Lot # | 语言 |
|---|---|---|---|---|
| Product Information Sheet | ClonaCell™-HY Medium A | 03801 | All | English |
| Special Protocol | ClonaCell™-HY Medium A | 03801 | All | English |
| Manual | ClonaCell™-HY Medium A | 03801 | All | English |
| Safety Data Sheet | ClonaCell™-HY Medium A | 03801 | All | English |
数据及文献
Publications (1)
Cell 2019 may
A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface.
Abstract
Abstract
Here, we describe the discovery of a naturally occurring human antibody (Ab), FluA-20, that recognizes a new site of vulnerability on the hemagglutinin (HA) head domain and reacts with most influenza A viruses. Structural characterization of FluA-20 with H1 and H3 head domains revealed a novel epitope in the HA trimer interface, suggesting previously unrecognized dynamic features of the trimeric HA protein. The critical HA residues recognized by FluA-20 remain conserved across most subtypes of influenza A viruses, which explains the Ab's extraordinary breadth. The Ab rapidly disrupted the integrity of HA protein trimers, inhibited cell-to-cell spread of virus in culture, and protected mice against challenge with viruses of H1N1, H3N2, H5N1, or H7N9 subtypes when used as prophylaxis or therapy. The FluA-20 Ab has uncovered an exceedingly conserved protective determinant in the influenza HA head domain trimer interface that is an unexpected new target for anti-influenza therapeutics and vaccines.
